Evidence that IL‐1β may have anti‐tumor activity was first presented 30 years ago, when intraperitoneal injection of recombinant human IL‐1β induced T‐cell‐dependent regression of subcutaneous SA1 sarcoma and L5178Y lymphomas in mice.161. This evidence concerns the gene IL1B and neoplasm.